Advertisement
Australia markets close in 2 hours 20 minutes

  • ALL ORDS

    7,852.30
    -85.20 (-1.07%)
     

  • ASX 200

    7,590.80
    -92.20 (-1.20%)
     

  • AUD/USD

    0.6524
    +0.0001 (+0.02%)
     

  • OIL

    83.79
    +0.22 (+0.26%)
     

  • GOLD

    2,345.10
    +2.60 (+0.11%)
     

  • Bitcoin AUD

    98,768.02
    +60.41 (+0.06%)
     

  • CMC Crypto 200

    1,390.19
    +7.62 (+0.55%)
     

  • AUD/EUR

    0.6083
    +0.0009 (+0.15%)
     

  • AUD/NZD

    1.0949
    -0.0009 (-0.08%)
     

  • NZX 50

    11,831.42
    -115.01 (-0.96%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,585.53
    +300.99 (+1.74%)
     

  • NIKKEI 225

    38,045.99
    +417.51 (+1.11%)
     

Miromatrix to Report Third Quarter 2021 Financial Results

Miromatrix Medical Inc.
·1-min read

EDEN PRAIRIE, Minn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2021 after market close on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers. Please reference Conference ID: 10161624. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/

About Miromatrix

Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com